Promoter hypermethylation of the cysteine protease RECK may cause metastasis of osteosarcoma

The present study examined the role of reversion-inducing cysteine-rich protein with Kazal motifs (RECK) promoter hypermethylation as a causative factor in metastasis of osteosarcoma. Using human pathological samples, it is demonstrated that RECK, a cysteine protease that reversibly regulates expression of matrix metalloproteases like matrix metallopeptidase 9 (MMP9), is transcriptionally inhibited in osteosarcoma, especially metastatic variants. This result comes from its promoter hypermethylation, as evaluated in the present study by methylation-specific PCR reaction. The expression of RECK was also significantly diminished in the metastatic variants of osteosarcoma. This downregulation of RECK in advanced grades of osteosarcoma and metastatic grades was also associated with the increased expression of invadosome-specific markers like MMP9, phospho-FAK, and integrins, suggesting the complex contributions of RECK in the prevention of metastasis and its downregulation as a causative factor in osteosarcoma metastasis.

[1]  S. Dry,et al.  Circulating tumor cells in sarcomas: a brief review , 2014, Medical Oncology.

[2]  Yong-Koo Park,et al.  Significance of MTA1 in the molecular characterization of osteosarcoma , 2014, Cancer and Metastasis Reviews.

[3]  C. Khanna,et al.  Role of ezrin in osteosarcoma metastasis. , 2014, Advances in experimental medicine and biology.

[4]  Young‐Mi Lee,et al.  Downregulation of ERK signaling impairs U2OS osteosarcoma cell migration in collagen matrix by suppressing MMP9 production , 2013, Oncology letters.

[5]  C. Peng,et al.  Clinical significance of RECK promoter methylation in pancreatic ductal adenocarcinoma , 2013, Tumor Biology.

[6]  Kanghua Li,et al.  EMT transcription factors: implication in osteosarcoma , 2013, Medical Oncology.

[7]  J. Bu,et al.  A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma , 2014, Tumor Biology.

[8]  Dahui Sun,et al.  MMP9 mediates MICA shedding in human osteosarcomas , 2011, Cell biology international.

[9]  David M. Thomas,et al.  RECK in osteosarcoma , 2011, Cancer.

[10]  Han-Soo Kim,et al.  RECK expression in osteosarcoma: correlation with matrix metalloproteinases activation and tumor invasiveness , 2007, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[11]  Wei Zhang,et al.  New molecular insights into osteosarcoma targeted therapy , 2013, Current opinion in oncology.

[12]  Xin Shi,et al.  Expression of matrix metalloproteinase regulator, RECK, and its clinical significance in osteosarcoma , 2010, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[13]  G. Rodan,et al.  Type beta transforming growth factor regulates expression of genes encoding bone matrix proteins. , 1989, Connective tissue research.

[14]  Lixin Wei,et al.  The Silencing of RECK Gene is Associated with Promoter Hypermethylation and Poor Survival in Hepatocellular Carcinoma , 2012, International journal of biological sciences.

[15]  O. P. Camargo,et al.  Correlation between the expression of vegf and survival in osteosarcoma , 2014, Acta ortopedica brasileira.